KUALA LUMPUR (Aug 18): Duopharma Biotech Bhd (KL:DPHARMA) reported a 48% earnings jump in the second quarter thanks to higher-margin products and stronger ringgit that lowered input costs.

Net profit for the three months ended June 30, 2026 (2QFY2026) was RM29.9 million compared to RM20.2 million in the same quarter in 2025, according to the pharmaceutical firm’s exchange filing. Gross margin widened five percentage-points to 42%, while revenue rose 5.7% to RM234.4 million.

“Duopharma Biotech’s resilient financial performance comes from a healthy order book, diversified revenue streams and strong participation in the public and private healthcare sector,” said chief executive officer Wan Amir-Jeffery Wan Abdul Majid.

To maintain growth, the company will continue to focus on cost management while maintaining diversified active pharmaceutical ingredient sourcing and inventory management among others, he added.

For the first six months, Duopharma’s net profit totalled RM60.6 million, an increase of 32.3% from RM45.8 million in the first half of 2025.

Revenue, however, declined 0.5% year-on-year to RM482.2 million, mainly due to lower insulin sales to the public sector following a one-off surge last year.

Duopharma declared an interim dividend of 1.5 sen per share, payable on Sept 21.

Shares of Duopharma paused for midday break on Tuesday, up one sen or 0.8% to RM1.24, giving the group a market capitalisation of RM1.19 billion.